Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.85 |
| ▸ | CA6 | P23280 | 5/20 | 0.85 |
| ▸ | CA7 | P43166 | 5/20 | 0.85 |
| ▸ | CA9 | Q16790 | 5/20 | 0.85 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.85 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.85 |
| ▸ | CA2 | P00918 | 4/20 | 0.85 |
| ▸ | CA4 | P22748 | 4/20 | 0.85 |
| ▸ | CA5A | P35218 | 4/20 | 0.85 |
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.85 |
| ▸ | CA3 | P07451 | 3/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.85 |
| ▸ | CA1 | P00915 | 2/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | TP53 | P04637 | 1/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trientine SCHEMBL1651076 | 1.00 | CA12 (0.85) | CA12CA6CA7CA9CA14 | |
| Hydrochloric Acid SCHEMBL18760070 | 0.92 | CA12 (0.85) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL10701650 | 0.92 | CA12 (0.85) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL8867083 | 0.92 | CA12 (0.85) | CA12CA6CA7CA9CA14 | |
| SCHEMBL27726151 | 0.92 | — | — | |
| SCHEMBL25340653 | 0.92 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL3840289 | 0.92 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL25342018 | 0.92 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL581603 | 0.92 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL10917234 | 0.92 | CA12 (1.00) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316150-A1 | METHOD FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY PATHOGEN-ASSOCIATED MOLECULAR PATTERN | SQ BIOPHARMA INC. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-114099540-B | Application of cationic polymer in preparation of medicines for eliminating intestinal microbial toxins and treating tumors | 成都施桂行医药科技有限责任公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230190662-A1 | Efficacy of a Gastro-Retentive Bile Acid Sequestrant Dosage Form | IRONWOOD PHARMACEUTICALS, INC. | 2023-06-22 | — | — | US | disclosed |
| WO-2023097980-A1 | USE OF CATIONIC POLYMER IN PREPARATION OF DRUG | 成都施桂行医药科技有限责任公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023040311-A1 | APPLICATION OF CATIONIC POLYMER IN PREPARATION OF DRUG FOR REMOVING INTESTINAL MICROBIAL TOXINS AND TREATING TUMORS | 成都施桂行医药科技有限责任公司 | 2023-03-23 | — | — | WO | disclosed |
| US-20220370367-A1 | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | IRONWOOD PHARMACEUTICALS INC (US) | 2022-11-24 | — | — | US | disclosed |
| CN-114767646-A | Effects of gastric retentive bile acid sequestrant formulation | 铁木医药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3991719-A1 | GASTRO-RETENTIVE SUSTAINED-RELEASE ORAL DOSAGE FORM OF A BILE ACID SEQUESTRANT | Ironwood Pharmaceuticals, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| US-20220110876-A1 | Gastro-Retentive Sustained-Release Oral Dosage Form of a Bile Acid Sequestrant | IRONWOOD PHARMACEUTICALS INC (US) | 2022-04-14 | — | — | US | disclosed |
| CN-114146184-A | Use of cationic polymers for the preparation of medicaments | 成都施桂行医药科技有限责任公司 | 2022-03-08 | — | — | CN | disclosed |
| EP-2478894-A2 | Compositions for treating esophageal disorders | Ironwood Pharmaceuticals, Inc. (US) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012027331-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME AND RELATED DISEASES AND DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110129433-A1 | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100179235-A1 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2009158625-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20090312302-A1 | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| EP-2124884-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008080092-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | UNITED STATES GOVERNMENT | 2003-02-13 | — | — | US | disclosed |
| US-6403576-B1 | CHOLESTEROL SYNTHESIS INHIBITOR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316150-A1 | METHOD FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY PATHOGEN-ASSOCIATED MOLECULAR PATTERN | FABP2, TLR2, TLR9 | CA12 1915/4885CA6 4127/4885CA7 4249/4885 |
| US-20110129433-A1 | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders | HRH2, GABRB1, GABRB3 | CA12 710/4885CA6 960/4885CA7 468/4885 |
| US-20090312302-A1 | Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders | SLC10A1, LIPC, FABP1 | CA12 1051/4885CA6 1155/4885CA7 1508/4885 |
| US-20030032578-A1 | Antifungal and antiparasitic compounds | PIGO, CAT, ERG28 | CA12 3870/4885CA6 2321/4885CA7 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.